An interventional study of Hybrid Argon Plasma Coagulation in Gastric Low Grade Intraepithelial Neoplasia, sponsored by Chinese University of Hong Kong. Recruiting at 1 site in Hong Kong. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2023-11-07.
Sponsored by Chinese University of Hong Kong · Not applicable, Interventional, and Treatment
This cohort study aims to investigate the clinical efficacy and safety of Hybrid APC for treatment of gastric low grade intramucosal neoplasia.
This cohort study aims to investigate the clinical efficacy and safety of Hybrid APC for treatment of gastric low grade intramucosal neoplasia. Successful ablation is defined as no evidence of local recurrence at 12 months after HybridAPC upon follow up endoscopy. This is defined as absence of LGIN, HGIN and cancer in biopsies obtained at all locations during followup endoscopy.
9,365 studies on the registry are indexed under Neoplasms; 2,489 are open to participants now.
This study's planned enrollment of 100 is above the median of 50 across 7,253 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →Chinese University of Hong Kong is the lead sponsor of 1,419 studies on the registry; 487 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
The Hybrid-Argon Plasma Coagulation probe combines waterjet technology with Argon Plasma Coagulation. The probe comprises a central water channel for the submucosa injection function and a peripheral gas channel for the Argon Plasma Coagulation function
Procedure: Hybrid Argon Plasma Coagulation
Argon Plasma Coagulation after water injection for local ablation
Complete ablation of gastric low grade intraepithelial neoplasia
Successful ablation is defined as no evidence of local recurrence at 12 months after HybridAPC upon follow up endoscopy. This is defined as absence of LGIN, HGIN and cancer in biopsies obtained at all locations during followup endoscopy.
Time frame: 12 months
Operative time
Time to complete the procedure
Time frame: 1 day
Intraoperative bleeding
Bleeding during the procedure as defined by Grade Definition 0 No bleeding 1. Less bleeding, could be auto-stopped or used by HibridAPC 2. Stop bleeding by using hot forceps 3. Stop bleeding by using clips
Time frame: 1 day
Pain after procedure
Pain after the procedure as defined by pain score Grade Definition 0 No pain, I Slight pain, II Moderate pain, III Severe pain, IV Extreme pain. V Unbearable pain
Time frame: 3 days
Development of new neoplasia
Development of new neoplasia including low grade intraepithelial neoplasia, high grade intraepithelial neoplasia and advanced gastric cancers
Time frame: 12, 24 and 36 months
Progression of Low grade intraepithelial neoplasia
Progression of the development of low grade intraepithelial neoplasia to high grade intraepithelial neoplasia or advanced gastric cancer
Time frame: 12, 24 and 36 months
Postoperative complications
Development of postoperative complications including bleeding and perforation
Time frame: 7 days
Number of HybridAPC procedures required for treatment
The number of Hybrid Argon Plasma Coagulation performed for complete ablation
Time frame: 12 months
Plan to share: Undecided
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chinese University of Hong Kong